Ananda Pharma Plc (AQSE:ANA) finance director Jeremy Sturgess-Smith talked with Proactive's Stephen Gunnion about the company's progress with MRX1, a promising treatment for chemotherapy-induced peripheral neuropathy (CIPN) and endometriosis pain. Ananda has completed the final GMP-certified batch needed for regulatory approval, marking a significant milestone in its clinical journey.
Sturgess-Smith explained, "What we've done is we've now completed all the preparatory work before we can manufacture MRX1 to deliver to patients," emphasising the upcoming trials in Edinburgh and Australia. The trials include CIPN and endometriosis studies at Edinburgh University, as well as a phase one pharmacokinetic (PK) study in Australia.
The next steps involve ethics submissions and discussions with the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to ensure compliance with regulatory standards. Approval from independent ethics panels will ensure the clinical trials meet ethical standards, while stability data from these trials will support potential licensing with global regulators, including the FDA in the US and the EMA in Europe.
Stay tuned to Proactive's YouTube channel for more updates on Ananda Pharma's clinical progress. Don't forget to like this video, subscribe to our channel, and enable notifications for the latest insights!
#AnandaPharma #MRX1 #ClinicalTrials #CIPN #Endometriosis #PharmaNews #Biotech #MHRA #FDA #Pharmacokinetics #ProactiveInvestors
